Gyre Therapeutics, Inc. (GYRE) scores 31 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $3.06, representing a 133% premium to fair value.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.